Overview

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Status:
Completed
Trial end date:
2016-04-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
Phase:
Phase 3
Details
Lead Sponsor:
Rigel Pharmaceuticals